2018
Michael E. Phelps, PhD (born August 24, 1939)
Wackers FJT, Corner H. Michael E. Phelps, PhD (born August 24, 1939). Journal Of Nuclear Cardiology 2018, 26: 34-35. PMID: 30382503, DOI: 10.1007/s12350-018-01492-z.Peer-Reviewed Original Research
1987
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy Seven-year experience using serial radionuclide angiocardiography
Schwartz R, McKenzie W, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz P, Berger H, Setaro J, Surkin L, Wackers F, Zaret B. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy Seven-year experience using serial radionuclide angiocardiography. The American Journal Of Medicine 1987, 82: 1109-1118. PMID: 3605130, DOI: 10.1016/0002-9343(87)90212-9.Peer-Reviewed Original ResearchConceptsClinical congestive heart failureCongestive heart failureVentricular ejection fractionAbsolute left ventricular ejection fractionLeft ventricular ejection fractionHeart failureEjection fractionDoxorubicin therapyMild congestive heart failureClinical predictor variablesDiscontinuation of doxorubicinTotal cumulative dosageHigh-risk patientsHigh-risk subsetMajority of patientsHigh cumulative doseCommunity hospital settingProportional hazards regressionSeven-year experienceCommunity hospital environmentSerial radionuclideLast followVentricular dysfunctionClinical outcomesRoutine therapy
1983
Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance
Choi B, Berger H, Schwartz P, Alexander J, Wackers F, Gottschalk A, Zaret B. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. American Heart Journal 1983, 106: 638-643. PMID: 6613807, DOI: 10.1016/0002-8703(83)90080-7.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionVentricular ejection fractionCongestive heart failureLeft ventricular performanceVentricular performanceEjection fractionAbnormal baselineHeart failureDoxorubicin therapyDoxorubicin cardiotoxicityRadionuclide angiocardiographyAbnormal left ventricular ejection fractionFinal left ventricular ejection fractionAntecedent cardiovascular diseaseSerial radionuclide studiesFirst-pass radionuclide angiocardiographyIdentification of patientsUse of doxorubicinSafe discontinuationThoracic radiationVentricular functionCancer patientsCumulative doseCardiovascular diseaseRadionuclide assessment